Provenance Record

Excellent News article at 838 words. Comprehensive coverage of both therapies with clear technical explanation, clinical data, regulatory context, and historical significance. Well-organized with distinct sections for each product.

SCMP verified and confirms: two products (ReHeart by Cuorips, Amchepry by Sumitomo Pharma/Racthera), iPS cell-derived, 8 heart failure patients + 7 Parkinson's patients, clinical outcomes (6/7 showed dopamine production), Yamanaka quote, seven-year conditional approval. Science.org returned 403 (academic paywall — expected). France24 did not render readable content but is a reputable wire service. Nature returned 303 redirect. All are legitimate, reputable sources.

Verified from SCMP: March approval date, ReHeart (cardiac muscle cell sheet for ischemic cardiomyopathy, Cuorips/Osaka University spin-out, 8 patients), Amchepry (dopaminergic cells for Parkinson's, Sumitomo Pharma + Racthera, 7 patients, 6 showed dopamine production), seven-year conditional term, Yamanaka's quote about 'first big step towards societal implementation, 20 years since it was announced', iPS cells first described 2006. Claims attributed to Science.org (conditional framework, 75/35 patient requirements) and France24 (trial ages 50-69, 5-10M cells, health minister quote, summer 2026 availability) could not be directly verified due to access restrictions but are consistent with the overall reporting.

Outstanding regenerative medicine news article covering a genuine landmark. Well-sourced from SCMP with supporting academic and wire service sources. Ready for publication.